US Bancorp’s Arcutis Biotherapeutics ARQT Stock Holding History

US Bancorp’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.7K	Sell	141 -1	-0.7%	-$23	﹤0.01%	3738
2026 Q1	$3.35K	Sell	142 -119	-46%	-$3.04K	﹤0.01%	3683
2025 Q4	$7.58K	Buy	+261	New	+$6.68K	﹤0.01%	3419
2025 Q3	–	Sell	-62	Closed	-$869	–	4016
2025 Q2	$869	Sell	62 -57	-48%	-$799	﹤0.01%	3965
2025 Q1	$1.86K	Buy	119 +95	+396%	+$1.34K	﹤0.01%	3898
2024 Q4	$334	Buy	+24	New	+$263	﹤0.01%	4051
2023 Q3	–	Sell	-80	Closed	-$762	–	3987
2023 Q2	$762	Buy	+80	New	+$888	﹤0.01%	3835
2023 Q1	–	Sell	-480	Closed	-$7.1K	–	4084
2022 Q4	$7.1K	Buy	480 +428	+823%	+$7.48K	﹤0.01%	3401
2022 Q3	$1K	Sell	52 -233	-82%	-$5.28K	﹤0.01%	3914
2022 Q2	$6K	Hold	285	–	–	﹤0.01%	3503
2022 Q1	$5K	Buy	+285	New	+$4.82K	﹤0.01%	3588
2021 Q4	–	Sell	-114	Closed	-$3K	–	4087
2021 Q3	$3K	Buy	114 +22	+24%	+$502	﹤0.01%	3759
2021 Q2	$3K	Buy	+92	New	+$2.59K	﹤0.01%	3708

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

US Bancorp's ARQT Position: Q2 2026 in Review

US Bancorp reduced its Arcutis Biotherapeutics (ARQT) stake by 0.7% in Q2 2026, selling an estimated $23 and leaving 141 shares worth $3.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3738.

US Bancorp first reported a position in ARQT in Q2 2021 and has held it in 13 quarters since. The position peaked at $7.58K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

US Bancorp held 141 shares of Arcutis Biotherapeutics worth $3.7K as of Q2 2026.
US Bancorp sold 1 Arcutis Biotherapeutics share in Q2 2026, an estimated $23.
Arcutis Biotherapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3738 holding.
US Bancorp first reported a position in Arcutis Biotherapeutics in Q2 2021 and has held it in 13 quarters since.
US Bancorp's Arcutis Biotherapeutics position peaked at $7.58K in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.